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We establish a novel method for the induction and collection of mesenchymal stem cells using a typical
cell surface marker, CD105, through adipogenesis from mouse ES cells. ES cells were cultured in a
medium for adipogenesis. Mesenchymal stem cells from mouse ES cells were easily identiﬁed by the
expression of CD105, and were isolated and differentiated into multiple mesenchymal cell types.
Mesenchymal stem cells showed remarkable telomerase activity and sustained their growth for a long
time with a high potential for differentiation involving skeletal myogenesis in vitro. When mesench-
ymal stem cells were transplanted into the injured tibialis anterior muscles, they differentiated into
skeletal muscle cells in vivo. In addition, they improved the vascular formation, but never formed
teratoma for longer than 6 months. Gene expression proﬁles revealed that mesenchymal stem cells lost
pluripotency, while they acquired high potential to differentiate into mesenchymal cell lines. They thus
indicate a promising new source of cell-based therapy without teratoma formation.
& 2011 International Society of Differentiation. Published by Elsevier Ltd. All rights reserved.1. Introduction
Mesenchymal stem cells (MSCs) have the potential to differ-
entiate into any mesenchymal cell type such as osteocytes,
chondrocytes, adipocytes and muscular cells. It is well known
that MSCs can be isolated from several adult tissues including
bone marrow and adipose tissues (Izadpanah et al., 2006; Fraser
et al., 2006; Kern et al., 2006; Schfﬂer and Bu¨chler, 2007; Satija
et al., 2007). Those isolated from bone marrow are termed bone
marrow-derived stem cells (BMSCs), and show a high potential
for differentiation into mesenchymal cells and also neuro-differ-
entiation capacity as well (Dezawa et al., 2005). BMSCs, however,
are quite limited in population and their invasive isolation
involves risks. Adipose tissues have proved to be a useful and
rich source of adipose tissue-derived mesenchymal stem cells
(ADSCs). Although ADSCs have shown therapeutic efﬁciency in
repairing damaged mesenchymal tissues, their isolation and
puriﬁcation from adult adipose tissue still involve complicated
and troublesome procedures. Furthermore, they readily differ-
entiate into adipocytes, osteocytes and chondrocytes but do not
easily differentiate into skeletal muscular cells (Dicker et al.,Society of Differentiation. Publish
w.isdifferentiation.org)
Sciences, Nagoya University
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rihashi).2005; Izadpanah et al., 2006; Kern et al., 2006; Bunnell et al.,
2008).
Mouse embryonic stem cells (M-ESCs), on the other hand, are
pluripotent, and their induction into adipocytes has been well
described (Dani et al., 1997; Kawaguchi, 2006). We initially
supposed that a part of MSCs, like ADSCs, would appear through
the process of differentiation into mesenchymal cell lines, such as
adipogenesis from undifferentiated M-ESCs. The aim of this study
was to establish a method for the induction and collection of
MSCs through adipogenesis from M-ESCs without genetic manip-
ulation. During the adipogenesis of M-ESCs, MSCs appeared to
possess high potential for differentiation into mesenchymal cell
lines including skeletal muscles both in vitro, and in vivo, but did
not exhibit pluripotency. We further conﬁrmed that these MSCs
showed a high telomerase activity lacking in MSCs from adult
tissue including BMCs and ADSCs. This advantage brought sus-
tained growth with high potential for differentiation into any
mesenchymal cell type in vitro. We also established that isolated
MSCs possess different properties from undifferentiated M-ESCs.
Rather than pluripotency, MSCs have displayed lineage-speciﬁc
differentiation into cells of mesenchymal origin.
MSCs from M-ESCs were easily identiﬁed by the expression of
CD105, which enabled us to obtain them in abundance. Our study
results suggest that M-ESCs became a new source of MSCs, with
their high differentiation potential conﬁrmed in vitro and in vivo.
They also enhanced vascular formation in recipient tissues after
transplantation without the risk of teratoma formation.ed by Elsevier Ltd. All rights reserved.
Fig. 1. Generation of MSCs from M-ESCs. (A) Schematic view of the induction and
sorting process of MSCs. After day 6, ES cells were cultured in induction medium.
When CD105þ cells increased and reached the maximum population (day 14),
they were isolated and sorted by a magnetic cell sorter (MACS). (B) Expression of
CD105 in ES cells. CD105þ cells were detectable after day 10. At day 14, they were
markedly increased. CD105 immunoreactivity was not expressed on the surface of
adipocytes stained with BODIPY at day 21. CD105þ cells were a few on day 14
when adipogenesis had not been induced (Ins/T3). (C) CD105þ cells also
express PDGFr-a, Thy-1 and Sca-1.
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2.1. M-ESCs
Mouse ES cells (G4-2; carrying the enhanced green ﬂuorescent
protein – EGFP – gene under the control of cytomegalovirus/
chicken b-actin promoter) were expanded in culture medium
termed ES-DMEM. That is Dulbecco’s modiﬁed Eagle’s medium
(Sigma; St. Louis, MO; www.sigma-aldrich.com) with 0.1 mM
non-essential amino acids (GIBCO; Carlsbad, CA; www.invitro
gen.com), 100 mM sodium pyruvate (GIBCO), 100 mM 2-mercap-
toethanol (Sigma), 0.5% antibiotic-antimycotic (GIBCO) containing
10% fetal bovine serum (FBS; Biological Industries, Kibbuiz, Israel;
www.bioind.com). For expansion of M-ESCs, 1000 U/mL of leuke-
mia inhibitory factor (LIF; Chemicon, Temecula, CA; www.milli
pore.com) was added in ES-DMEM.
2.2. Animals
Immunodeﬁcient mice (SCID), 8-week-old, were purchased
from Japan Charles River (Yokohama, Japan; www.crj.co.jp) and
used under the guidelines for the Animal Care and Use of Nagoya
University Graduate School of Medicine.
2.3. Generation, sorting and passage of MSCs
For the induction of adipogenesis, M-ESCs were incubated for
2 days without LIF and compacted to form embryoid bodies (EBs)
in hanging drops. On the following 2 days, they were exposed to
107 M all-trans retinoic acid (RA; Sigma) in culture medium
followed by washing for 2 days without RA. The EBs were plated
onto gelatin-coated dishes and then incubated with 1.7 mM
insulin (Sigma) and 0.3 mM 3,3,5-triiodo-L-thyronine (Sigma) in
ES-DMEM after day 6 (Fig. 1). Developing EBs were detached from
the dishes, isolated with 5 mM EDTA in phosphate buffer saline
(pH 7.4) and then sorted by a Magnetic Cell Separation System
(MACS; Miltenyi Biotec, Auburn, CA; www.miltenyibiotec.com)
using both an anti-CD105 antibody (R&D Systems, Minneapolis
MN; www.RnDSystems.com) and an anti-rat antibody conjugated
with magnetic beads (Miltenyi Biotec). Sample preparation,
magnetic labeling and magnetic separation with mini-MS
columns were conducted according to the manufacturer’s instruc-
tions. Some samples were labeled with anti-CD105 antibody
conjugated with phycoerythrin (PE) (R&D systems) and then
incubated with anti-PE Micro Beads. Samples were processed
for magnetic separation using mini-MS columns and analyzed by
a Flow Cytometer, FACS Calibur (BD Biosciences, Franklin Lakes, NJ;
www.bd.com). After MACS separation, cells non-speciﬁcally adher-
ing to the MACS columns by the highly viscous force were removed
using a short-time (4 h) culture in non-coating dishes. Floating
cells were then transferred to coating dishes for culture as MSCs.
MSCs were expanded using medium STK2 (DS Pharma Biomedical;
Osaka, Japan; www.ds-pharma.co.jp). When passage was carried
out every other day, MSCs were counted and examined for their
differentiation potential by induction to mesenchymal cell lineages
per below.
2.4. Isolation and culture of ADSCs from adipose tissues
ADSCs were isolated from adipose tissues surrounding testes.
The protocol mainly followed that of an earlier report (Lin et al.,
2006). Fat tissues were dissected and minced in PBS containing
10% penicillin and streptomycin (Wako Chemicals; Osaka, Japan;
www.wako-chem.co.jp). They were then incubated with an
enzyme solution containing 1 mg/mL type I collagenase (Wako),
1% BSA (Sigma) and 10% penicillin and streptomycin (Wako) inPBS for 60 min at 37 1C. After stopping the enzyme reaction by
cold PBS, cells released from adipose tissues were ﬁltered through
a cell strainer with 100 mm meshes (Falcon) and collected by
centrifugation at 300g for 10 min. The pellet was resuspended in
STK1 (DS Pharma Biomedical), a medium for a primary culture of
mesenchymal stem cells, and cells were seeded on the plastic
tissue culture dish (Falcon). After 24 h, ﬂoating cells were
removed and attached cells were maintained in STK2 as ADSCs.
2.5. Fluorescent immunostaining
Cells and tissues were ﬁxed with 4% paraformaldehyde for either
15 min or 3 h. Cryosections of tissues and cells adhering to dishes
were processed for ﬂuorescent immunostaining. Samples were incu-
bated with the ﬁrst antibodies followed by Alexa-labeled secondary
antibodies. Either anti-CD105 rat monoclonal antibody (1:100; R&D),
anti-myosin heavy chain mouse monoclonal antibody (1:200;
Upstate, Lake Placid, NY; www.upstate.com), anti-M-cadherin mouse
monoclonal antibody (1:20; Invitrogen; Carlsbad, CA; www.invitroge.
com), anti- collagen type II polyclonal antibody (1:200, Cosmo. Bio,
LSL, Tokyo, Japan; www.cosmobio.co.jp), anti- ﬂk-1 antibody (1:100,
Signalway Antibody, Pearland, TX; www.signalwayantibody.com),
anti-EGFP/GFP polyclonal antibody (1:100; Novus Biologicals, Inc.;
www.NovusBio.com), anti-Telomerase antibody (1:500, EMD Chemi-
cals, Gibbstown, NJ. www.calbiochem.com), anti-PDGFr-a polyclonal
antibody (1:200, Santa Cruz Biotechnological Inc.; www.scby.com),
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abcam.com) and anti-CD90/Thy1 monoclonal antibody (1:200,
Abcam) were used as a ﬁrst antibody. The secondary antibody was
Alexa Fluor 594 goat anti-rat IgG (1:400; Molecular Probes, Leiden,
Netherlands; www.probes.com), Alexa Fluor 594 goat anti-mouse
IgG (1:400; Molecular Probes), Alexa Fluor 594 goat anti-rabbit IgG
(1:400; Molecular Probes) or Alexa Fluor 488 anti-rabbit IgG (1:400;
Molecular Probes). Some samples were counterstained with DAPI
(1:1000; KPL; Gaithersburg, MD; www.kpl.com) just before mounting
with FluoromountTM (DBS, Pleasanton, CA; www.dibisys.com). For
double staining of some adipose cells, 0.2% BODYPY493/503 (Mole-
cular probes) was applied for 10 min after staining with anti-CD105
antibody. Samples were observed using the ﬂuorescent microscope,
Axio Observer (Zeiss, Tokyo Japan; www.zeiss.co.jp) and then
recorded with a Zeiss Axio Vision 4.6 (Zeiss). When ﬁrst antibodies
were omitted, speciﬁc immunostaining was not observed.2.6. Histological staining
Differentiated cells in vitro were ﬁxed with 4% paraformaldehyde
for 15–30min. Adipose cells were stained with 0.3% Oil Red O
(Sigma) diluted to 60% with D.W. They were counterstained with
hematoxylin. Calcium in osteogenic cells was stained with 1% Alizarin
red (Sigma) adjusted to pH 6.36–6.40 by anmonic water (Sigma).
Chondrocytes were stained with 1% Alcian blue 8GX (Sigma) in 3%
acetic acid (Sigma) after tissues were processed for cryosections.2.7. RT-PCR
Total mRNAs from tissues or cells were extracted by RNeasy
micro kit (Qiagen, Valencia, CA; www.quiagen.com) according to the
manufacturer’s instructions. RNAs were immediately reverse tran-
scripted to cDNA using SuperScript
TM
II (Qiagen). For PCR, primer
couples used are shown in Table 1. PCR products were ampliﬁed to
30 cycles at 94 1C for 30 s, 60 1C for 30 s and 72 1C for 60 s.2.8. Karyotyping
MSCs after 10 passages were incubated in media containing
0.2 mg/mL corcemid (Chemicon, Temecula, CA; www.millipore.
com) for 6 h at 37 1C, 5% CO2, trypsinized from the dish, resus-
pended in 0.075 mol/L KCl and incubated for 20 min at 37 1C, then
ﬁxed in 3:1 methanol acetic acid, and dropped on the slide glass,
which was dried at room temperature, dyed with Giemsa liquid
(Sigma) for 10–20 min, and observed under a microscope.Table 1
PCR primer sequences.
Gene Forward R
GAPDH CCCATCACCATCTTCCAGGA T
PPARc AAGAGCTGACCCAATGGTTG G
LPL GGGCTCTGCCTGAGTTGTAG T
Runx2 CCCAGCCACCTTTACCTACA C
Osterix ACTACCCACCCTTCCCTCAC G
aggrecan CCAAGTTCCAGGGTCACTGT T
Col2a1 ACACCGAGGTTTCACTGGAC C
MyoD1 AGTGAATGAGGCCTTCGAGA C
Myf5 AGACGCCTGAAGAAGGTCAA T
Myogenin ACCTTCCTGTCCACCTTCAG C
M-cadherin CAAGTTCACTGGGAGGGTG C
Sox2 AACGCCTTCATGGTATGGTC A
Oct4 AAAGGTGTTCAGCCAGACCA C
Stat3 TGGTGTCCAGTTTACCACGA T
Nanog AAGTACCTCAGCCTCCAGCA C2.9. Quantitative telomerase activity assay
Telomerase activities of MSCs after MACS, undifferentiated ES
cells, ADSCs from adipose tissues and mouse blood cells which
were sucked from a heart (500 mL of blood) and subsequently
separated by a centrifuge (1000 rpm 5 min) were measured using
quantitative telomerase detection kit, which is categorized in
telomeric repeat ampliﬁcation protocol (TRAP; Allied Biotech, Inc.,
Vallejo, CA; www.alliedbiotechinc.com). The same number of
cells (1105 cells) were lysed and processed for telomerase
reaction followed by real-time PCR according to the manufac-
turer’s instructions. Real-time PCR (35 cycles) was carried out
by a real-time cycler Mx3000P (Stratagene, La Jolla, CA, www.
stratagene.com). Quantitative results were analyzed using stan-
dard curve by template TSR Threshold cycle (CT).2.10. Induction to mesenchymal cell lineages
After sorting by MACS, both MSCs (CD105þ cells) and non-
MSCs (CD105 cells) were differentiated into mesenchymal cells,
respectively. For adipogenesis, they were allowed to continue to
incubate in ES-DMEM containing 1.7 mM insulin (Sigma) and
0.3 mM 3,3,5-triiodo-L-thyronine (T3; Sigma). For osteogenesis,
the cells were cultured with 0.1 mM dexamethasone (Sigma),
10 mM b-glycerol phosphate (Kanto Kagaku; Tokyo, Japan;
www.kanto.co.jp), and 200 mM ascorbic acid (Sigma) in ES-DMEM.
For induction to skeletal muscle, cells after MACS were cultured in
the ES-DMEM with 5% Knockout Serum Replacement (KSR Invi-
trogen) instead of 10% FBS. For induction to chondrocytes, cells
were centrifuged in 5-mL tubes and cultured with ES-DMEM
containing 10 ng/mL TGFb3 (Sigma) 100 nM PTH (Sigma), and 5%
FBS in those same tubes. After induction for 2 weeks, the
differentiation potential of CD105þ cells was measured. Adipo-
genic differentiation (n¼5) was demonstrated by the accumula-
tion of neutral lipid vacuoles using Oil Red O. Osteogenic
differentiation (n¼5) was conﬁrmed by the deposition of miner-
alized matrix stained by Alizarin Red. Chondrogenic differentiation
(n¼5) was conﬁrmed by the formation of a sphere and the
secretion of cartilage-speciﬁc proteoglycans stained with Alcian
blue. Ten ﬁelds (395,411 mm2 each) were chosen at random in
each sample, and the ratio of positive area was calculated by a
software BZ-II Analyzer (Keyence Co.; Osaka, Japan; www.key
ence.co.jp). Myogenic differentiation (n¼5) was demonstrated by
expression of MHC immunoreactivity, and calculated by the
proportion of MHC-positive cell numbers per total cell numbers
stained with DAPI. ADSCs from adipose tissues were also
processed as mentioned above.everse Product size
TGTCATACCAGGAAATGAGC 733
GATCCGGCAGTTAAGATCA 296
CATGAGCAGTTCTCCGATG 316
AGCGTCAACACCATCATTC 308
GTAGGGAGCTGGGTTAAGG 360
CTAGCATGCTCCACCACTG 398
GTCGTGCTGTCTCAAGGTA 365
TGGGTTCCCTGTTCTGTGT 533
GGAGAGAGGGAAGCTGTGT 436
ACTCCCTTACGTCCATCGT 579
CTCTGCAGCCTCCATAAA 550
TGTAGGTCTGCGAGCTGGT 515
TCATACTCTTCTCGTTGGG 369
GGCGGCTTAGTGAAGAAGT 469
GTAAGGCTGCAGAAAGTCC 424
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After sorting of MSCs, 1105 of cells were injected into tibialis
anterior muscles of SCID mice 24 h after wound by direct clamp-
ing. After either 1 or 2 weeks of injection, the mice were sacriﬁced
and ﬁxed with 4% paraformaldehyde, and muscles were
embedded into OCT compound (Tissue Tek; Sakura Finetechnical
Co.; Tokyo, Japan; www.sakurajp.co.jp) to be frozen. Cryosections
(6 mm) were used for immuno-ﬂuorescent staining. Tissues were
also processed for HE staining.
For teratoma formation, 1105 of either MSCs or undiffer-
entiated M-ESCs were transplanted into the subcutaneous tissue
of inguinal regions of SCID mice. After 1 month, the epidermis
was cut and opened to expose the inguinal regions. Transplanted
areas were observed and injected cells were searched by a
dissection microscope combined with ﬂuorescence. Teratoma
was dissected and processed for either ﬂuorescent or HE staining
on frozen-sections.
2.12. Microarray analysis
Total RNAs from MSCs separated by MACS (600 ng; A260/
A280¼2.05) and undifferentiated M-ESCs (4600 ng A260/
A280¼1.83) were extracted using an RNeasy micro kit. RNAs
were converted to biotinylated cRNA and hybridized to sentrix
mouse ref-8 expression BeadChips (Illumina mouse Ref.8; Illu-
mina Japan, Tokyo, Japan; www.illuminakk.co.jp). More than
24,000 mouse genes were probed in a ref-8 array. Detection and
expression analyses were carried out by Moritex (Yokohama,
Japan; www.pgx-glyco.com). The purity of the samples and
evidences of high performance are shown in the supplemental
data (Supplements).3. Results
3.1. Appearance and sorting of MSCs
After 10 days of induction to adipogenesis, small, round
CD105þ cells appeared at day 10, began to increase and reachedFig. 2. Separation and increase of MSCs. During the adipogenesis of M-ESCs, MSCs (CD
increased the population through passages. (A) Puriﬁcation of CD105þ cells before and
conﬁrmed by a ﬂow cytometer (FACS). (B) MSCs showed a ﬂat and bipolar cell shap
substantially increased the population through 12 passages, after which they gradually
showed a shorter growth period. (D) High expression of CD105 in MSCS did not alter du
of the references to color in this ﬁgure legend, the reader is referred to the web versiotheir maximum population on day 14. Adipocytes then increased
and CD105þ cells alternately decreased. Since double staining
with CD105 and BODIPY demonstrated that adipocytes did not
express CD105. Continuous observation of CD105þ cells from day
14 to day 21 by live staining with CD105 revealed that CD105þ
cells became adipose cells increasing oil droplets in their cyto-
plasm (data not shown). Therefore, sorting by MACS was usually
carried out on day 14 (Fig. 1A). With continuous culture without
adipogenesis after day 6, quite a few CD105þ cells appeared
(Fig. 1B). Since CD105þ cells demonstrated other markers of
mesenchymal stem cells such as Thy-1, PDGFr-a, and Sca-1, we
denoted CD105þ cells as MSCs (Fig. 1C). The efﬁciency of sorting
by MACS was conﬁrmed by FACS analysis, and more than 91% of
CD105þ MSCs cells were collected after MACS. The adhesion
separation of non-speciﬁc cells after MACS further increased the
purity of MSCs. Sorted MSCs were uniformly bipolar in shape,
similar to that of the MSCs previously reported (Fig. 2A, B). MSCs
had continued to increase the cell population and the cell number
was counted at each passage every other day. They grew sequen-
tially during more than 12 passages, and the population gradually
reached the plateau level. During their growth, MSCs had sus-
tained the expression of CD105 and the ratio of the positive cells
was more than 96% (Fig. 2C, D). On the other hand, ADSCs isolated
from adipose tissue expressed CD105 like MSCs soon after the
isolation (Supplement Fig. 1). They increased the cell population
until 5 passages, reached a plateau, and then attenuated after
7 passages (Fig. 2C).
3.2. High potential for differentiation into mesenchymal cells
MSCs showed a high potential for differentiation into
mesenchymal cells such as adipocytes, osteogenic cells, chondro-
cytes and skeletal muscle cells (Fig. 3A–D). Both MSCs (CD105þ
cells) and non-MSCs (CD105 cells) separated by MACS were
differentiated into mesenchymal cells and compared with each
other. After induction of adipogenesis, more than 97% of MSCs
differentiated into adipocytes. Non-MSCs, however, did not pro-
duce large Oil Red O-positive oil droplets. MSCs turned Alizarin
Red-positive after induction of osteogenesis. Non-MSCs did not
survive under the condition of osteogenesis and disappeared.105þ cells) appeared and they were isolated with a high probability, purity and
after MACS. Isolation of more than 91% of CD105þ cells by MACS separation was
e that resembled previously described MSCs. (C): After MACS, MSCs (blue line)
reached the maximum population. ADSCs from adipose tissue (broken blue line)
ring passages, and more than 96% of cells continued expression. (For interpretation
n of this article.)
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ball-like aggregations. When a cryo-section of the aggregations
was stained with Alcian blue, the matrix surrounding the chon-
drocytes turned blue. The matrix produced by MSCs expressed
collagen type II immunoreactivity, while non-MSCs did not form
cell aggregations and were not stained with either Alcian blue or
anti-collagen type II antibody. When MSCs differentiated into
skeletal muscle cells, they became thin and ﬁbrous, and began to
express M-cadherin. They ran in the same direction and distrib-
uted parallel to each other. After 3 weeks of induction, they began
to fuse together to form myotubes that expressed myosin heavy
chain (MHC) immunoreactivity. DAPI staining revealed the for-
mation of multinuclear cells. They ﬁnally constructed sarcomeres
exhibiting bands with myosin and actin ﬁlaments regularlyarrayed. A few non-MSCs expressed M-cadherin immunoreactivity,
but did not form myotubes under the same condition (Fig. 3A–D).
Their potential for differentiation into mesenchymal cells was
conﬁrmed by the expression of their speciﬁc mRNAs detected by
RT-PCR as well. After the induction of adipocytes and the formation
of lipid droplets, MSCs expressed PPAR-g and LPL mRNAs. Follow-
ing the formation of osteogenic cells, they displayed both Runx-2
and Osterix mRNAs. The small ball-like structures observed after
the induction of chondrogenesis expressed Collagen2 and agglycan
mRNAs. Skeletal muscle cells differentiating from MSCs expressed
Myogenin, M-cadherin, MyoD and Myf5 mRNAs (Fig. 3Aii–Dii).
The high potential for differentiation into mesenchymal
cells was sustained for a long time until 10 passages. More than
90.0% of MSCs were able to differentiate into mesenchymal
cells. The respective differentiation efﬁcacies were approximately
97.76% of adipocytes, 94.9% of chondrocytes, and 93.0% of
osteocytes (Fig. 4A). After induction into skeletal muscle cells,
about 33.61% of cells expressed MHC immunoreactivity. However,
ADSCs isolated from adipose tissue showed extremely low differ-
entiation potential at passage 5 while they increased the popula-
tion sequentially. The respective differentiation efﬁcacies were
approximately 18.06% of adipocytes, 8.0% of osteocytes and 1.23%
of skeletal muscle cells (Fig. 4A). Our MSCs, in addition, grown by
10 passages, showed normal diploid karyotype when analyzed by
a G-staining method (Fig. 4B).3.3. Higher activity of telomerase
Undifferentiated M-ESCs and MSCs showed high telomerase
activity, though the enzyme distribution patterns were different
from each other as shown in Fig. 5. Immunostaining of telomerase
in M-ESCs demonstrated high activity in the peri-nuclear cytoplasm
(Fig. 5A). Although only a little reactivity was shown in the nucleus
of the M-ESCs, telomerase immunoreactivity of MSCs was mainly
demonstrated in the nucleus (Fig. 5B). High telomerase activity in
both cell types was indicated by immunostaining and was con-
ﬁrmed by quantitative telomerase activity assay. The same number
of undifferentiated M-ESCs, MSCs sorted by MACS, ADSCs isolated
from adipose tissues and blood cells, were assayed using a quanti-
tative telomerase detection kit, and activity per 1105 cells was
calibrated and analyzed by a standard TSR control value (Fig. 5C,D).
The activity of 1105 MSCs was 0.09370.001 amoles/mL and was
lower than 0.2570.008 amoles/mL in M-ESCs. However, both cells
showed extremely high activity compared to ADSCs and blood cells,Fig. 3. Differentiation of MSCs (CD105þ cells) and non-MSCs (CD105 cells)
under adipogenic, osteogenic, chondrogenic or myogenic conditions. CD105þ
cells differentiated into either adipocytes, osteogenic cells, chondrogenic cells or
skeletal muscle cells; however, CD105 cells did not show any sign of differ-
entiation into these cells. (A) Adipogenesis. (i) CD105þ cells became adipocytes
with many oil droplets stained with oil red O, whereas CD105 cells did not
differentiate into adipocytes containing oil red O-positive droplets. (ii) RT-PCR also
demonstrated adipogenesis of CD105þcells by PPARg and LPL. (B) Osteogenesis.
(i) Bone formation from CD105þ cells was demonstrated by alizarin red staining,
whereas CD105 cells did not grow under the osteogenic condition. CD105 cells
disappeared after a few days of culture. (ii) RT-PCR also demonstrated osteogenic
differentiation from CD105þ cells by Runx2 and Osterix. (C) (i) Chondrogenesis or
the formation of cartilage from CD105þ cells was prominent with proteoglycans
in extracellular matrix detected by Alcian blue staining. CD105 cells did not
form Alcian-blue positive matrix. (ii) RT-PCR demonstrated chondrocytes origi-
nated from CD105þ cells by Collage 2 and Aggrecan. (D) Myogenesis. (i) CD105þ
cells showed muscle differentiation and became myoblasts with M-cadherin
immunoreactivity after myogenic induction. They fused with each other
and formed multi-cellular myotubes (insertion) with MHC immunoreactivity.
(ii) RT-PCR also demonstrated myogenesis of CD105þ cells by MyoD, Myf5,
Myogenin and M cadherin. (E) Expression of pluripotency-associated genes (Nanog,
Stat3, Oct4 and sox2) was low in CD105þ cells by RT-PCR. All expressions were
normalized by GAPDH. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
passage
Fig. 4. Potential differentiation into mesenchymal cell types and nuclear pattern during continuing passages of MSCs. After MACS, MSCs maintained a high potential for
differentiation into mesenchymal cells. (A) MSCs maintained high differentiation potential; more than 90% of cells responded to either adipogenesis, osteogenesis or
chondrogenesis until passage 10. Almost 33% of MSCs differentiated into skeletal muscles after induction. ADSCs from adipose tissue show low differentiation potential for
mesenchymal cell lines indicated by open circles. About 18.6% of ADSCs differentiated into adipocytes after induction ( ). About 8.0% of ADSCs were induced to
differentiate into osteocytes ( ). Only 1.23% of ADSCs differentiated into skeletal muscles ( ). (B) Normal diploid karyotypes were maintained after 10 passages of MSCs.
No abnormal nuclear pattern was observed during long-time culture.
N. Ninagawa et al. / Differentiation 82 (2011) 153–164158i.e. 0.0004370.00001 amoles/mL and 0.0001670.00001 amoles/mL,
respectively. Though MSCs had high telomerase activity, it was
lower than that of undifferentiated M-ESCs (Fig. 5D).
3.4. Transplantation to immunodeﬁcient mice; differentiation
potential in vivo and teratoma formation
Potential differentiation into mesenchymal cells in vivo was
examined by transplantation to SCID mice. MSCs were trans-
planted into injured tibialis anterior skeletal muscles 24 h after
clamping. Transplanted cells located at the injected area were
aggregated into a colony and did not move to other regions during
the following 1 or 2 weeks. They were clearly distinguished from
host cells by their EGFP immunoreactivity (Fig. 6). After 1 week of
transplantation, EGFP-positive cells at the center of the colony
assumed a small and round appearance with a nucleus and made
contact with each other in the cross-section of the tibialis anterior
muscle. At the peripheral region of the colony, EGFP-positive cells
grew larger, some of them expressing M-cadherin immunoreactiv-
ity. At the outermost region of the colony, they became even larger
and showed MHC immunoreactivity. Their nuclei were located at
the center of the cells and occasionally appeared as multinuclear
cells in the cross-section (Fig. 6A). After 2 weeks of transplantation,
MHC-positive cells increased and became large enough to involve
several nuclei in the cross-section. From the HE staining, many
blood vessels invaded the colony of transplanted cells. Flk1-
positive cells indicating blood vessels frequently overlapped with
EGFP immunoreactivity, suggesting that transplanted cells had
differentiated into the endothelial cells of blood vessels (Fig. 6B).
When undifferentiated M-ESCs (1105 cells) were trans-
planted to subcutaneous inguinal regions, M-ESCs formed clearly
identiﬁable teratoma after 1 month and mice showed a spastic
gait (Fig. 7A). The teratoma tissue showed high EGFP ﬂuorescent,
when it was observed under the ﬂuorescent dissection micro-
scope (Fig. 7A insertion). Tissue section stained with HE indicated
rosettes of neural ectoderm, mesodermal cartilage-like structure,endodermal gut epithelium with goblet cells and ciliated respira-
tory epithelium (Fig. 7B–E). On the other hand, the same number
of implanted MSCs did not form teratoma 1 month after injection.
We could not ﬁnd any EGFP expressing tissues or cell aggregation
at the subcutaneous layer (Fig. 7F). After 6 months of transplanta-
tion, MSCs did not form any clumps of teratoma subcutaneously,
and the host mouse survived without any trouble.
3.5. Distinct properties from undifferentiated M-ESCs; gene
expression proﬁles by DNA microarray and RT-PCR
MSCs showed an extremely high expression in genes related to
the processes of differentiation into mesenchymal cells (Fig. 8A and
supplement Table 1). The following genes were highly expressed in
MSCs: Fndc3b, Pparg, Adrb1and Tgfb1i1 were related to adipogen-
esis, while Enpp1, Ihh and Csf1were involved in osteogenesis. Bmp3
and Sox9were related to chondrogenesis, andMyoD1 andMyogenin
were linked to myogenesis. On the other hand, genes required for
pluripotency were expressed at very low levels compared to
undifferentiated M-ESCs (Fig. 8B). For example, Sox2, Oct4, Stat3
and Nanog were highly expressed in undifferentiated M-ESCs, but
not in MSCs; the data were conﬁrmed by RT-PCR (Fig. 3E). Besides
CD105, cell surface markers of mesenchymal cells that were
commonly expressed in MSCs were prominent as previously
described. Low-expressing genes were also at a low level in the
proﬁles (see Fig. 8C). Among immune response-related genes, MHC
I genes were positive, while MHC II genes were negative (Fig. 8C).
Other genes with high or low expression are listed in Table 2.4. Discussion
4.1. Expression and speciﬁcity of CD105
CD105, also known as endoglin, is a homodimeric-type trans-
membrane glycoprotein that binds to TGF-b1 and TGF-b3 to form
Un differentiated ES cells
DAPITelomerase Merge
CD105+ cells
DAPI CD105Telomerase Merge
10µm
Quantitative real-time PCR
Y= -2.774*Log(X) + 39.69
RSq: 0.994
Standard
M-ESCs
CD105+ MSCs
ADSCs
Blood cells
Telomerase activity (amol/µL)
10µm
Fig. 5. High telomerase activity in MSCs. MSCs have high telomerase activity in their nuclei. (A) Undifferentiated M-ESCs showed high immunoreactivity in their
cytoplasm. Telomerase activity (green) was mainly located in DAPI (blue)-negative cytoplasm. (B) MSCs (red) also have strong telomerase immunoreactivity (green) in
their nuclei (blue), conﬁrmed in the merged image. (C) Telomerase activity in 1105 cells of undifferentiated M-ESCs ( ), MSCs ( ), ADSCs from adipose tissue ( ) and
blood cells ( ) were measured by quantitative telomerase detection kit. The relative real-time threshold cycles (CT) and logarithmic plot of TSR control standard threshold
indicate high telomerase activities in undifferentiated M-ESCs and MSCs. (D) Calculated telomerase activities per 1105 cells were compared in the graph.
Undifferentiated M-ESCs demonstrated the highest activity. MSCs showed an extremely high concentration compared to both ADSCs and blood cells representing mouse
adult tissue/cells. Inactivation of telomerase by heat treatment (85 1C for 10 min) made for a loss of detectable telomerase activity. N.D. indicates non-detectable activity.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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signaling plays important roles in cell growth, differentiation and
migration, and is also known as a functional marker for theisolation of MSCs including ADSCs (Kern et al., 2006; Schfﬂer and
Bu¨chler, 2007). Almost all reports describing MSCs have demon-
strated the expression of CD105 on the cell surface, and in fact
Fig. 6. Myogenic potential of MSCs in vivo. (A) MSCs were transplanted into injured skeletal muscles (tibialis anterior muscles) of immune compromised SCID mouse after
24 h of clamping. After 1 week of transplantation, some of EGFP-positive cells expressed M-cadherin immunoreactivity (upper panels). At the peripheral region of the
injured muscle, many myosin heavy chain (MHC)-positive cells appeared and they were large cells involving several nuclei in the cross-section. Some MHC-positive cells
expressed EGFP (lower panels) in the transplantation area. (B) Flk-1-positive cells indicating blood vessels frequently overlapped with EGFP immunoreactivity. Arrows
indicate same cells showing double positive. Asterisks designate double positive cells in each panel.
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(Schfﬂer and Bu¨chler, 2007; Trivedi and Hematti, 2008). Actually,
the Lian group isolated CD105þ cells as MSCs from human ES
cells (Lian et al., 2007). After the completion of adipogenesis,
mature adipocytes did not express CD105. Fully differentiated
chondrocytes that showed collagen-type II immunoreactivity did
not express CD105 (Majumdar et al., 2000). MSCs or progenitor
cells in any type of mesenchymal tissues likely express CD105 as
a common marker, whereas mature mesenchymal cells them-
selves lose the expression. Our protocol for generation of MSCs
through partial adipogenesis increased CD105þ cells (Fig. 1B),
so it is one of the efﬁcient ways to obtain MSCs from M-ESCs.
CD105, however, is not a speciﬁc marker for MSCs. Many reports
have indicated that endothelial cells of blood vessels present
CD105 as well (Neumu¨ller et al., 2006; Rohde et al., 2006;
Perlingeiro, 2007). In our system, another group of cells with
CD105 appeared at day 18 with morphological features quite
different from those of our sorting cells. A second group of cells
resembled long, slender endothelium. Those endothelium-like
cells were readily distinguished from the ﬁrst group of cells by
their shape and the time of their appearance. Therefore, MACS
sorting at day 14 during adipogenesis was a very critical time.
CD105þ cells obtained by MACS after 8–10 days of induction of
adipogenesis were a distinctly homogeneous population in the
present study. Therefore, CD105 was established as a useful
marker to separate and collect MSCs in our system. The isolation
efﬁciency rate with MACS was more than 91%. This was furtherenhanced using a technique of adhesion separation after sorting
by MACS as described in the Methods section.
Recently, a few groups reported that a part of neuroepithelial
cells were the origin of MSCs (Takashima et al., 2007; Billon et al.,
2007). One of them indicated that transiently expressing Sox1 and
PDGFr-a cells gave rise to MSCs in vivo and demonstrated it
in vitro using a differentiation protocol similar to ours (Billon
et al., 2007). Though they did not describe the expression of
CD105 in their MSCs, we presume their MSCs are similar to ours.
Actually, our MSCs expressed PDGFr-a (Fig. 1C).
4.2. Potential differentiation into mesenchymal cells, especially
skeletal muscle
Our MSCs demonstrated a high potential for differentiation
into mesenchymal-type cells, i.e., adipocytes, chondrocytes,
osteogenic cells and skeletal muscles in vitro and in vivo. Their
differentiation potential indicates that CD105þ cells sorted by
MSCS were MSCs, and that was subsequently conﬁrmed as such
by their gene-expression proﬁle. Our MSCs were differentiated
and sorted during adipogenesis, suggesting that they corre-
sponded to ADSCs. Our MSCs were easily differentiated into
skeletal muscles, though both MSCs and ADSCs isolated from
tissues in vivo have been described as hardly differentiating into
muscles or as requiring forced expression of MyoD for the
completion of myogenesis (Majumdar et al., 2000; Kawaguchi,
2006; Lian et al., 2007; Goudenege et al., 2009). Our data on
µm
µ
µm
µm
Rosette
Cartilage
Fig. 7. Teratoma formation potential. MSCs prevented teratoma formation. The same numbers of 1105 either M-ESCs or MSCs were transplanted into subcutaneous
inguinal regions of SCID mice. (A) M-ESCs that formed teratoma after 1 month of transplantation are indicated by an arrow and surrounded by a dotted line. (Insertion)
Teratoma was illuminated by EGFP indicating injected cells under the ﬂuorescent dissection microscope. (B) Teratoma involved rosette of neural ectoderm shown by H-E
staining on the section. (C) Cartilage-like tissue originated from mesoderm was also involved. (D) Gut epithelium with goblet cells originated from endoderm. (E) Ciliated
columnar epithelium originated from endoderm was also involved in the teratoma. (F) The mouse in which MSCs were transplanted did not show any sign of teratoma.
Asterisks indicate quadriceps femoris muscles.
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reports. In general, the requirement for the provision of speciﬁc
MSCs does not in fact involve the potential for skeletal muscle
differentiation (Schfﬂer and Bu¨chler, 2007). The prominent poten-
tial of our MSCs from M-ESCs to differentiate into skeletal muscle
probably depends on the medium containing insulin and T3 for
adipogenesis before sorted by MACS. Skeletal muscle cells are
sensitive to insulin and the IGF family as growth factors. IGF-II
promotes myogenesis through Rho-ROCK activity and induces
myoD1 (Rosen and MacDougald, 2006; Wilson and Rotwein,
2006). We found that myoD1 expression was sustained at quite
a high level in our MSCs by DNA array analysis. The receptors of
insulin and/or IGFs may be highly expressed before induction of
myogenesis in our MSCs. In fact, DNA array analysis showed a
high expression of IGF receptor I and II genes in our MSCs
(Fig. 8A). Culture conditions generating our MSCs showed advan-
tages over myogenesis in our method. Recently, MSCs were
developed from human ES cells using CD105 as a useful marker
of MSCs (Lian et al., 2007). Their protocol did not involve
adipogenic induction by the medium containing insulin and T3.
The potential for differentiation into skeletal muscle cells both
in vitro and in vivo from the human MSCs was not described at
all. Actually, gene expression proﬁles by DNA array did not show
any high IGF score and their receptor family members (Lian et al.
2007, Supplementary data 2). Therefore, one of the advantages of
our protocol and our MSCs is easy derivation of skeletal muscle
cells compared to previous methods.
4.3. Advantages of MSCs derived from M-ESCs
Besides easy myogenesis, our MSCs have several more suitable
features than other MSCs reported. Analysis of the telomeraseactivity in our MSCs demonstrated high activity but lower
than that of undifferentiated M-ESCs (Fig. 5). Telomerase main-
tains telomere length that is shortened during cell division and
limits the life span of the cell. Many reports have indicated
that telomerase expression in ES cells and cancer stem cells is
quite high; however, the expression in MSCs and ADSCs from
either human or rodents is extremely low. Some MSCs completely
lack telomerase activity (Simonse et al., 2002; Zimmermann
et al., 2003; Serakinci et al., 2008; Shay and Wright, 2010;
Flores and Blasco, 2010). The low telomerase activity resulted
in short life span, cellular senescence and arrested growth
(Simonse et al., 2002). When telomerase was ectopically
expressed in MSCs, the mean telomere length was increased
and differentiation potential was activated. Further, it extended
the proliferative life span. Therefore, high telomerase activity in
our MSCs has advantages over other MSCs obtained from adult
tissue in vivo.
Our MSCs showed sustained cell growth for long-time culture
of more than 10 passages (almost 1-month culture) without
abnormal karyotype alteration. During long-time culture MSCs
also kept the potential for differentiation into mesenchymal cell
lineages (Fig. 4). Usually, MSCs have never maintained their
growth and differentiation potential over such a long time
(Javazon et al., 2004; Kern et al., 2006; Peng et al., 2008). Long
stability under the culture condition may arise from high telo-
merase activity. Indeed, ADSCs isolated from adipose tissue in our
experiment showed a low telomerase activity and a short growth
period with lower differentiation potential than those of our
MSCs. Similar differentiation potential of ADSCs was presented
in the report we referred to regarding isolation (Lin et al., 2006).
Thus, long-time culture with a high potential for differentiation is
a useful feature of our MSCs.
Fig. 8. Gene expression analysis using microarray. Log2 ratios of normalized averaged intensity values are shown here. Plus bars indicate genes expressed much higher in
MSCs than in undifferentiated M-ESCs. Minus bars indicate vice versa. (A) Genes in the process of differentiation into mesenchymal cells were over-represented in MSCs.
Numerical data are also shown in the Supplement Table 1. (B) Pluripotency-associated genes were over-presented in undifferentiated M-ESCs. (C) Cell surface marker
genes of MSCs reported previously including MHC class I and class II are shown here. MSCs expressed most of the positive cellular markers of MSCs described and failed to
express most of the negative cellular markers.
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After injection into the injured tibialis anterior, MSCs were
differentiated into skeletal muscles in vivo. These ﬁndings suggest
that the fate of MSCs ultimately depends on their micro-environ-
ments as already described (Schfﬂer and Bu¨chler, 2007). Induction
factors from host tissues surrounding MSCs regulate their differ-
entiation into a certain mesenchymal cell type. Furthermore,
MSCs also differentiated into blood vessels in the regeneration
of skeletal muscle tissue in the tibialis anterior. Blood vessels in
regenerating tissues were incorporated into both MSCs and host
cells. Recently, the transplantation of MSCs has been reported as
promoting regeneration after transplantation and showing sup-
porting effects by their angiogenic potential (Banas et al., 2008;Constantin et al., 2009). MSCs form vessels by themselves, while
also secreting signiﬁcant amounts of angiogenesis mediators,
such as VEGF, HGF, FGF-2, TGF-b and angiopoietin-1 (Oswald
et al., 2004; Wang et al., 2006). Further studies of the molecular
mechanisms of angiogenesis by MSCs should result in improved
MSC cell therapies.
Although M-ESCs after 1 month of transplantation into the
subcutaneous tissue of inguinal regions formed severe teratoma,
MSCs did not made any teratoma under the same environment
in vivo, and transplanted animals were kept alive without any trouble
for more than 6 months. This is also supported by gene expression
proﬁle lacking genes of pluripotency. Avoidance of teratoma forma-
tion is the most important, useful and advantageous issue for
regeneration therapy.
Table 2
DNA microarray gene expression.
Symbol Fold change Accession Deﬁnition
Genes highly expressed
gene in MSC rather than M-ESC
Inhba 13.03409 NM_008380.1 Inhibin beta-A
Col6a3 12.24762 NM_009935.1 Procollagen, type VI, alpha 3
Hoxc6 11.98335 NM_010465.2 Homeo box C6
Actg2 11.52712 NM_009610.1 Actin, gamma 2, smooth muscle, enteric
Hoxb7 10.40413 NM_010460.2 Homeo box B7
Megf10 10.36746 NM_001001979.1 Multiple EGF-like-domains 10
Vcam1 10.32063 NM_011693.2 Vascular cell adhesion molecule 1
Gpr176 10.25647 NM_201367.2 G protein-coupled receptor 176
Rbms3 10.20973 NM_178660.2 RNA binding motif, single stranded interacting protein
Prl2c2 10.14448 NM_031191.1 Prolactin family 2, subfamily c, member 2
Nrn1 10.01144 NM_153529.1 Neuritin 1
Gpr149 9.974584 NM_177346.1
Tnfaip2 9.948781 NM_009396.1 Tumor necrosis factor, alpha-induced protein 2
Mylk 9.791423 NM_139300.3 Myosin, light polypeptide kinase
S100a7a 9.786008 NM_199422.1 S100 calcium binding protein A7A
Sdpr 9.729962 NM_138741.1 Serum deprivation response
Sprr2k 9.704087 NM_011477.2 Small proline-rich protein 2K
Cdkn2a 9.677835 NM_001040654.1 Cyclin-dependent kinase inhibitor 2A
Galntl4 9.552616 NM_173739.3 UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase-like 4
Unc5c 9.52692 NM_009472.3 unc-5 homolog C (C. elegans)
Genes highly expressed in
M-ESC rather than MSC
Spats1 8.52956 NM_027649.2 Spermatogenesis associated serine-rich 1
Ly6g6e 7.99615 NM_027366.1 Lymphocyte antigen 6 complex, locus G6E
Gm1967 7.95735 NM_001033452.3 Gene model 1967 (NCBI)
Dennd1c 7.53239 NM_153551.1 DENN/MADD domain containing 1C
Neurod1 7.52994 NM_010894.2 Neurogenic differentiation 1
Ms4a6d 7.43048 NM_026835.2 Membrane-spanning 4-domains, subfamily A, member 6D
Dhx30 7.41958 BC016202
Ldhc 7.34123 NM_013580.4 Lactate dehydrogenase C
Gm1967 7.32303 NM_001033452.2 Gene model 1967 (NCBI)
Ly6g6d 7.27484 NM_033478.2 Lymphocyte antigen 6 G6D
Klk1b5 7.25304 NM_008456.2 Kallikrein 1-related peptidase b5
Oas1g 7.22758 NM_011852.2 20–50 oligoadenylate synthetase 1G
Adap1 7.21927 NM_172723.4 ArfGAP with dual PH domains 1
Cd2 7.0898 NM_013486.2 CD2 antigen
4931417G12Rik 6.94193 NM_027633.1 RIKEN cDNA 4931417G12 gene
Myo1f 6.90633 NM_053214.1 Myosin IF
Tmprss5 6.80187 NM_030709
Defcr20 6.71048 NM_183268.3 Defensin-related cryptdin 20
Klk1b26 6.70529 NM_010644.1 Kallikrein 1-related petidase b26
St8sia1 6.6358 NM_011374.2 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1
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from M-ESCs
MSCs were compared to undifferentiated M-ESCs. Our MSCs
showed typical MSC and ADSC gene expression proﬁles. The high
potential of our MSCs for differentiation into mesenchymal cells
was conﬁrmed by the adequate levels of gene expression proﬁles
in adipogenic, osteogenic, chondrogenic and myogenic genes. It is
important to note that MSCs expressed not only one cell type but
also others among the mesenchymal cells. Under appropriate
conditions the balance is tipped, leading to a cascade that
promotes the fate of one cell while repressing those of others.
In the present study, MSCs maintained the balance between genes
related to several cell types. Cell surface makers including MHC
classes I and II were also similar to MSCs reported previously
(Blanc et al., 2003; Puymirat et al., 2009). This suggests a
modulation of immune cell responses that could be therapeuti-
cally useful. Further investigation is warranted.
In contrast, the expression of genes maintaining undifferentia-
tion such as Sox2, oct4, stat3 and Nanogwas at very low levels, and
this ﬁnding was corroborated by RT-PCR. Most data from DNA
arrays were similar to other MSCs or ADSCs reported (Olivier
et al., 2006; Lian et al., 2007). MSCs lost pluripotency and
obtained high potential for differentiation into mesenchymalcells. This characteristic feature, therefore, can also be beneﬁcial
to transplantation in avoiding teratoma formation.
In summary, we developed MSCs with a high potential for
differentiation into mesenchymal cell lineages, including skeletal
muscles in vitro from M-ESCs using CD105 as a cell surface marker.
Depending on their surrounding micro-environments in vivo, MSCs
differentiated into skeletal muscles of injured tibialis anterior mus-
cles. They also enhanced vasculogenesis by differentiation into
endothelial cells or by the induction of blood vessels from surround-
ing tissues. Their gene expression proﬁles indicated low pluripotency,
thus avoiding teratoma formation, and all their properties proved
very beneﬁcial to cell-derived regeneration and therapeutic usage.Acknowledgments
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